Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AKBA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Standard of care phosphate-lowering therapy | Hyperphosphatemia | Phase 4 · NCT04922645 | Completed |
| Ferric Citrate 1 gram Oral Tablet | Hyperphosphatemia | Phase 4 · NCT04922645 | Completed |
| Vadadustat 900mg | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | Phase 2/3 · NCT07086755 | Recruiting |
| Vadadustat 1200mg | Nonintubated Acute Respiratory Distress Syndrome (ARDS) | Phase 2/3 · NCT07086755 | Recruiting |
| Vadadustat (AKB-6548) | Anemia of Chronic Kidney Disease | Phase 3 · NCT06901505 | Completed |
| Mircera® | Anemia Associated With Chronic Kidney Disease (CKD) | Phase 3 · NCT04707768 | Completed |
| Ferric Citrate 1 GM Oral Tablet [AURYXIA] | Anemia, Iron Deficiency | Phase 3 · NCT05085275 | Completed |
| Erythropoiesis-Stimulating Agent (ESA) | Anemia of Chronic Kidney Disease | Phase 3 · NCT06901505 | Completed |
| Erythropoiesis Stimulating Agent | Anemia of Chronic Kidney Disease | Phase 3 · NCT06520826 | Completed |
| ADX-097 | IgA Nephropathy | Phase 2 · NCT06419205 | Recruiting |
| Vadadustat TIW | Anemia | Phase 2 · NCT03799627 | Completed |
| Praliciguat (Part B) | Focal Segmental Glomerulosclerosis | Phase 2 · NCT07268638 | Recruiting |
| Praliciguat (Part A) | Focal Segmental Glomerulosclerosis | Phase 2 · NCT07268638 | Recruiting |
| IW-1973 | Type 2 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 · NCT03217591 | Completed |
| Probenecid | Drug Interaction Potentiation | Phase 1 · NCT03801746 | Completed |
| Adefovir | Drug Interaction Potentiation | Phase 1 · NCT03801759 | Completed |
Also used in these trials (approved or third-party drugs, not AKBA's own candidates): Darbepoetin Alfa, Epoetin Alfa, Calcium Acetate, Celecoxib, Digoxin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AKBA holds $159.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AKBA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 19,219,819 | 6.92% | 2025-12-31 |
| Vanguard Capital Management LLC | Institution (13F) | 11,327,392 | 4.08% | 2026-09-30 |
| Acadian Asset Management. LLC | Institution (13F) | 8,970,363 | 3.23% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 6,345,692 | 2.29% | 2026-09-30 |
| AQR Capital Management, LLC | Institution (13F) | 6,294,526 | 2.27% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 6,069,090 | 2.19% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 5,295,074 | 1.91% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 4,423,717 | 1.59% | 2026-09-30 |
| John P. Butler CEO and President, Director · +3.04M options |
Insider | 3,878,492 | 1.40% | 2026-08-06 |
| Vanguard Portfolio Management LLC | Institution (13F) | 3,537,072 | 1.27% | 2026-09-30 |
| Steven Keith Burke SVP, Chief Medical Officer · +612,300 options |
Insider | 948,432 | 0.34% | 2026-02-02 |
| Erik Ostrowski SVP, CFO, CBO & Treasurer · +320,000 options |
Insider | 616,616 | 0.22% | 2026-06-29 |
Share count 277,663,875 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-06 filed 2026-08-10 |
Butler John P. |
Option exercise (M) | 350,000 | $0.63 | 3,718,564 |
| 2026-08-06 filed 2026-08-10 |
Butler John P. |
Option exercise (M) | 350,000 | – | – |
| 2026-06-29 filed 2026-07-01 |
Ostrowski Erik |
Sale (S) | 56,019 | $1.11 | 616,616 |
| 2026-06-17 filed 2026-06-22 |
ROGERS MICHAEL W |
Award (A) | 35,700 | – | 197,429 |
| 2026-06-17 filed 2026-06-22 |
ZUMWALT LEANNE M |
Award (A) | 35,700 | – | 145,100 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AKBA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →